Xinkang Wang

Summary

Affiliation: Wyeth Research
Country: USA

Publications

  1. ncbi An optimized murine model of ferric chloride-induced arterial thrombosis for thrombosis research
    Xinkang Wang
    Department of Thrombosis Research, Bristol Myers Squibb Company, Princeton, NJ 08543, USA
    Thromb Res 115:95-100. 2005
  2. ncbi Imaging and molecular biomarkers of vulnerable atheromatous plaques
    Xinkang Wang
    Wyeth Research, Translational Medicine, 500 Arcola Road, S2324, Collegeville, PA 19426, USA
    Biomark Med 1:23-35. 2007
  3. ncbi Assessment of arterial stiffness, a translational medicine biomarker system for evaluation of vascular risk
    Xinkang Wang
    Discovery Translational Medicine, Wyeth Research, Collegeville, PA 19426, USA
    Cardiovasc Ther 26:214-23. 2008
  4. ncbi Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis
    Xinkang Wang
    Department of Thrombosis Biology, Bristol Myers Squibb Company, 311 Pennington Rocky Hill Road, Pennington, NJ 08534, USA
    J Thromb Thrombolysis 23:41-9. 2007
  5. ncbi Lipopolysaccharide augments venous and arterial thrombosis in the mouse
    Xinkang Wang
    Discovery Translational Medicine, Wyeth Research, Collegeville, PA 19426, USA
    Thromb Res 123:355-60. 2008
  6. ncbi Quantification of platelet composition in experimental venous thrombosis by real-time polymerase chain reaction
    Xinkang Wang
    Department of Thrombosis Biology, Bristol Myers Squibb Company, Pennington, NJ 08534, USA
    Thromb Res 119:593-600. 2007
  7. ncbi Significant neuroprotection against ischemic brain injury by inhibition of the MEK1 protein kinase in mice: exploration of potential mechanism associated with apoptosis
    Xinkang Wang
    Department of Cardiovascular Sciences, Bristol Myers Squibb Company, Wilmington, Delaware 19880 0400, USA
    J Pharmacol Exp Ther 304:172-8. 2003
  8. ncbi Inhibition of tumor necrosis factor-alpha-converting enzyme by a selective antagonist protects brain from focal ischemic injury in rats
    Xinkang Wang
    Department of Thrombosis Research, Bristol Myers Squibb Company, P O Box 5400, Princeton, NJ 08543 5400, USA
    Mol Pharmacol 65:890-6. 2004
  9. ncbi CD44 deficiency in mice protects brain from cerebral ischemia injury
    Xinkang Wang
    Departments of Cardiovascular Sciences and Neurosciences, Bristol Myers Squibb Company, Wilmington, Delaware 19880 0400, USA
    J Neurochem 83:1172-9. 2002
  10. ncbi Inhibition of factor Xa reduces ischemic brain damage after thromboembolic stroke in rats
    Xinkang Wang
    Department of Cardiovascular Sciences, Bristol Myers Squibb Company, Wilmington, Del, USA
    Stroke 34:468-74. 2003

Detail Information

Publications22

  1. ncbi An optimized murine model of ferric chloride-induced arterial thrombosis for thrombosis research
    Xinkang Wang
    Department of Thrombosis Research, Bristol Myers Squibb Company, Princeton, NJ 08543, USA
    Thromb Res 115:95-100. 2005
    ..Thus, the purpose of this study was to refine the ferric-chloride-induced thrombosis model to be better suited for thrombosis research...
  2. ncbi Imaging and molecular biomarkers of vulnerable atheromatous plaques
    Xinkang Wang
    Wyeth Research, Translational Medicine, 500 Arcola Road, S2324, Collegeville, PA 19426, USA
    Biomark Med 1:23-35. 2007
    ..This review focuses on recent advances for the use of circulating molecular biomarkers and imaging modalities to assess atherosclerotic vulnerable plaques in both preclinical models and clinical conditions...
  3. ncbi Assessment of arterial stiffness, a translational medicine biomarker system for evaluation of vascular risk
    Xinkang Wang
    Discovery Translational Medicine, Wyeth Research, Collegeville, PA 19426, USA
    Cardiovasc Ther 26:214-23. 2008
    ..This article will provide a comprehensive review of the recent advance on assessment of arterial stiffness as a translational medicine biomarker for cardiovascular risk...
  4. ncbi Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis
    Xinkang Wang
    Department of Thrombosis Biology, Bristol Myers Squibb Company, 311 Pennington Rocky Hill Road, Pennington, NJ 08534, USA
    J Thromb Thrombolysis 23:41-9. 2007
    ..The strong ex vivo fibrinolytic activity of TAFI deficiency or TAFIa inhibition by PCI provides a biomarker of TAFIa inhibition that tracks in vivo antithrombotic efficacy...
  5. ncbi Lipopolysaccharide augments venous and arterial thrombosis in the mouse
    Xinkang Wang
    Discovery Translational Medicine, Wyeth Research, Collegeville, PA 19426, USA
    Thromb Res 123:355-60. 2008
    ..Here, murine models of vena cava thrombosis and carotid arterial thrombosis augmented by lipopolysaccharide (LPS) were established and characterized to study the association between inflammation and thrombosis...
  6. ncbi Quantification of platelet composition in experimental venous thrombosis by real-time polymerase chain reaction
    Xinkang Wang
    Department of Thrombosis Biology, Bristol Myers Squibb Company, Pennington, NJ 08534, USA
    Thromb Res 119:593-600. 2007
    ..In this study a sensitive and reliable method to characterize the cellular components of experimental thrombi was developed using real-time polymerase chain reaction (PCR)...
  7. ncbi Significant neuroprotection against ischemic brain injury by inhibition of the MEK1 protein kinase in mice: exploration of potential mechanism associated with apoptosis
    Xinkang Wang
    Department of Cardiovascular Sciences, Bristol Myers Squibb Company, Wilmington, Delaware 19880 0400, USA
    J Pharmacol Exp Ther 304:172-8. 2003
    ..Our data suggest that the inhibition of MEK1/2 results in neuroprotection from reperfusion injury and that this protection may be associated with the reduction in apoptosis...
  8. ncbi Inhibition of tumor necrosis factor-alpha-converting enzyme by a selective antagonist protects brain from focal ischemic injury in rats
    Xinkang Wang
    Department of Thrombosis Research, Bristol Myers Squibb Company, P O Box 5400, Princeton, NJ 08543 5400, USA
    Mol Pharmacol 65:890-6. 2004
    ..Our data suggest that inhibition of TACE might be a potential therapeutic strategy for neuroprotection after focal ischemic stroke...
  9. ncbi CD44 deficiency in mice protects brain from cerebral ischemia injury
    Xinkang Wang
    Departments of Cardiovascular Sciences and Neurosciences, Bristol Myers Squibb Company, Wilmington, Delaware 19880 0400, USA
    J Neurochem 83:1172-9. 2002
    ..Our data provide new evidence on the potential role of CD44 in brain tissue in response to ischemia and may suggest that this effect might be associated with selective reduction in inflammatory cytokines such as interleukin-1beta...
  10. ncbi Inhibition of factor Xa reduces ischemic brain damage after thromboembolic stroke in rats
    Xinkang Wang
    Department of Cardiovascular Sciences, Bristol Myers Squibb Company, Wilmington, Del, USA
    Stroke 34:468-74. 2003
    ..In the present study we describe the effect of a novel, potent, and selective FXa inhibitor, DPC602, on brain damage and neurobehavioral consequence in a rat thromboembolic model of stroke...
  11. ncbi Multimodal biomarker investigation on efficacy and mechanism of action for the mammalian target of rapamycin inhibitor, temsirolimus, in a preclinical mammary carcinoma OncoMouse model: a translational medicine study in support for early clinical developm
    Xinkang Wang
    Imaging Biomarker Laboratory, Translational Medicine, Pfizer, Collegeville, Pennsylvania, USA
    J Pharmacol Exp Ther 339:421-9. 2011
    ....
  12. ncbi Investigational anti-inflammatory agents for the treatment of ischaemic brain injury
    Xinkang Wang
    Bristol Myers Squibb Company, Discovery Biology, 311 Pennington Rocky Hill Road, Pennington, NJ 08534, USA
    Expert Opin Investig Drugs 14:393-409. 2005
    ....
  13. ncbi Up-regulation of secretory leukocyte protease inhibitor (SLPI) in the brain after ischemic stroke: adenoviral expression of SLPI protects brain from ischemic injury
    Xinkang Wang
    Department of Thrombosis Research, Bristol Myers Squibb Company, 311 Pennington Rocky Hill Road, Pennington, NJ 08534, USA
    Mol Pharmacol 64:833-40. 2003
    ..01). These data suggest that the ischemia-induced expression of SLPI might play a neuroprotective role in focal stroke, possibly because of rapid inhibition of activated proteases and its suppression in inflammatory response...
  14. ncbi Multimodal magnetic resonance imaging for assessing evolution of ischemic penumbra: a key translational medicine strategy to manage the risk of developing novel therapies for acute ischemic stroke
    Juan C Chavez
    Discovery Translational Medicine, Wyeth Research, Collegeville, Pennsylvania 19468, USA
    J Cereb Blood Flow Metab 29:217-9. 2009
    ..This could serve as a biomarker indicative of neuroprotective potential and could increase likelihood of success in clinical studies by allowing selection of patients who are most likely to respond to therapy...
  15. ncbi Technologies of disease-related gene discovery using preclinical models of stroke
    Xinkang Wang
    Department of Thrombosis Research, Bristol Myers Squibb Company, Princeton, NJ, USA
    Methods Mol Med 104:253-64. 2005
    ..Identification of stroke-related gene expression will facilitate the understanding of the molecular basis of stroke pathogenesis and may provide a novel therapeutic intervention of the disease...
  16. ncbi Missing steps in the STAIR case: a Translational Medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke
    Giora Z Feuerstein
    Wyeth Research, Collegeville, Pennsylvania 19426, USA
    J Cereb Blood Flow Metab 28:217-9. 2008
    ..Finally, rational patient selection and new outcome scales tailored in an adaptive design model must be evaluated...
  17. ncbi Pharmacogenomic, physiological, and biochemical investigations on safety and efficacy biomarkers associated with the peroxisome proliferator-activated receptor-gamma activator rosiglitazone in rodents: a translational medicine investigation
    Xinkang Wang
    Discovery Translational Medicine, Pfizer, Collegeville, Pennsylvania, USA
    J Pharmacol Exp Ther 334:820-9. 2010
    ..Taken together, this study suggests a limited predictive power of these preclinical models in respect to observed clinical adverse effects associated with RGZ...
  18. ncbi Correlation between 2- and 3-dimensional assessment of tumor volume and vascular density by ultrasonography in a transgenic mouse model of mammary carcinoma
    Lei Zhao
    Discovery Translational Medicine, Wyeth Research, 500 Arcola Rd, Collegeville, PA 19426, USA
    J Ultrasound Med 29:587-95. 2010
    ..We hereby investigated the 2D and 3D sonographic correlation for tumor volume and vascular density confirmed by histologic assessment in the polyoma virus middle T antigen (PyMT) mouse model of mammary carcinoma...
  19. ncbi Comparative analysis of various platelet glycoprotein IIb/IIIa antagonists on shear-induced platelet activation and adhesion
    Xinkang Wang
    Department of Cardiovascular Sciences, Bristol Myers Squibb Company, Experimental Station, Wilmington, Delaware 19880 0400, USA
    J Pharmacol Exp Ther 303:1114-20. 2002
    ..The clinical significance of this phenomenon awaits further investigation...
  20. ncbi Mitogen-activated protein kinase-activated protein (MAPKAP) kinase 2 deficiency protects brain from ischemic injury in mice
    Xinkang Wang
    Department of Cardiovascular Sciences, Bristol Myers Squibb Company, Wilmington, Delaware 19880 0400, USA
    J Biol Chem 277:43968-72. 2002
    ..Our data provide new evidence for the involvement of MAP kinase pathway in focal ischemic brain injury and suggest that this effect might be associated with the expression of interleukin-1beta in the ischemic brain tissue...
  21. ncbi Biomarkers of vulnerable atheromatous plaques: translational medicine perspectives
    Xinkang Wang
    Discovery Translational Medicine, Wyeth Research, Collegeville, Pennsylvania, USA
    Adv Clin Chem 50:1-22. 2010
    ....
  22. ncbi Recombinant adenoviral expression of dominant negative IkappaBalpha protects brain from cerebral ischemic injury
    Lin Xu
    Department of Cardiovascular Sciences, Bristol-Myers Squibb Company, Experimental Station, E400/3418, Wilmington, DE 19880-0400, USA
    Biochem Biophys Res Commun 299:14-7. 2002
    ..01, n=8). These data provide further evidence for the role of NF-kappaB/IkappaB in ischemic brain injury and suggest that inhibition of NF-kappaB is neuroprotective in focal stroke...